CX157

CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA).[1] As of 2007 it was in phase II clinical trials for the treatment of depression.[2] In 2013, work on the drug was terminated.

CX157
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H8F4O4S
Molar mass348.27 g·mol−1
3D model (JSmol)
  (verify)

References

  1. Fielding R, Mielach F, Free J, Pande A (2007). Pharmacokinetics and oral bioavailability of CX157, a reversible selective MAO-A inhibitor, in primates (PDF). 2007 AAPS Annual Meeting & Exposition. Archived from the original (PDF) on 2011-05-26. Retrieved 2009-06-14.
  2. Clinical trial number NCT00739908} for "A Study of CX157 (TriRima) for the Treatment of Depression (CX157-200)" at ClinicalTrials.gov



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.